OralParenteralDosed ingredient Cosmetic cross-reference

Phytonadione

CAS 84-80-0

Phytonadione (CAS 84-80-0) is a Phase 4 pharmaceutical compound with 1 bioactivity target and 161 adverse event associations.

SOURCE NLM DailyMed

Label records

SOURCE EMBL-EBI ChEMBL

Bioactivity

SOURCE DrugCentral

Adverse signals

161

SOURCE IUPHAR/BPS

PubMed IDs

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name

Phytonadione

CAS Number

84-80-0

UNII

S5Z3U87QHF

InChIKey

MBWXNTAXLNYFJB-NKFFZRIASA-N

ChEMBL ID

CHEMBL1550

Molecule Type

Small molecule

Source Match

EMBL-EBI ChEMBL (INCHIKEY)

black box warningdosed ingredientnatural productoralparenteral

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 4 (Approved)

Approved or marketed human pharmaceutical use is represented in the source phase field.

ChEMBL CHEMBL1550 | Small molecule

SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →

SOURCE EMBL-EBI ChEMBL 4 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

Target	Activity	Value	Assays	Organism
-	AC50	27248.89375 nM	32	-
-	Potency	47053.56666666667 nM	6	-
-	IC50	15000 nM	1	-
Alpha-synuclein Transporter	IC50	4.82	-	Homo sapiens

SOURCE DrugCentral 80 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PT	Drug AE	LLR	MedDRA
Appendicolith	164	545.925	10074458
Infective pulmonary exacerbation of cystic fibrosis	155	424.063	10070608
Appendicitis	172	411.607	10003011
Ascites	262	399.643	10003445
Multiple organ dysfunction syndrome	285	355.085	10077361
Cardiogenic shock	184	340.877	10007625
Abdominal distension	232	233.055	10000060
Ventricular fibrillation	130	228.213	10047290
Sepsis	342	223.767	10040047
Blood phosphorus increased	88	217.772	10050196
Stress	174	190.568	10042209
International normalised ratio increased	146	145.161	10022595
Hyponatraemia	207	139.127	10021036
Cystic fibrosis	39	97.083	10011762
Abdominal pain	291	92.09	10000081
Coagulopathy	76	87.034	10009802
Blood uric acid increased	51	83.334	10005861
Toxic epidermal necrolysis	80	83.043	10044223
General physical health deterioration	225	82.496	10049438
Myasthenia gravis	46	82.316	10028417
Constipation	240	81.936	10010774
Injury associated with device	32	70.721	10069803
Drug therapy	21	66.373	10063370
Hyperphosphataemia	33	65.056	10020711
Hepatic failure	85	64.29	10019663
Pain	92	62.882	10033371
Analgesic therapy	18	57.394	10053469
Sleep disorder therapy	18	57.028	10040990
Rheumatoid arthritis	8	52.559	10039073
Factor V inhibition	13	50.928	10056335
Drug ineffective	213	50.8	10013709
Arthropathy	7	48.02	10003285
Hypophosphataemia	42	45.967	10021058
Activated partial thromboplastin time prolonged	35	45.513	10000636
Hepatic encephalopathy	44	45.171	10019660
Contraindicated product administered	7	45.003	10078504
Joint swelling	24	44.004	10023232
Haemoptysis	65	42.196	10018964
Vomiting	350	41.615	10047700
Acute hepatic failure	48	41.468	10000804
Dry mouth	88	40.499	10013781
Hyperbilirubinaemia	44	40.369	10020578
Prothrombin time prolonged	35	39.914	10037063
Respiratory failure	129	39.649	10038695
Cholestasis	58	38.384	10008635
Renal vascular thrombosis	8	37.74	10072226
Treatment failure	11	37.185	10066901
Abdominal discomfort	29	36.282	10000059
Toxicity to various agents	39	35.691	10070863
Systemic lupus erythematosus	8	35.485	10042945

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE NLM RxNorm 3 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

Name	RxCUI	Type	Source
Phytonadione	8308	SU	MTHSPL
PHYTONADIONE	8308	SU	MTHSPL
phytonadione	8308	SY	RXNORM

SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Phytonadione used for in pharmaceutical contexts?

Phytonadione (CAS 84-80-0) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Phytonadione?

Phytonadione has 161 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Appendicolith, Infective pulmonary exacerbation of cystic fibrosis, Appendicitis, Ascites, Multiple organ dysfunction syndrome. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Phytonadione also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Phytonadione with EU status "permitted".

What clinical phase is Phytonadione in?

Phytonadione is rendered with ChEMBL max phase 4 (approved).

What bioactivity targets are documented for Phytonadione?

Phytonadione has 4 bioactivity rows in this page query. Rendered target entries include Alpha-synuclein.